<SEC-DOCUMENT>0000950170-25-113599.txt : 20250908
<SEC-HEADER>0000950170-25-113599.hdr.sgml : 20250908
<ACCEPTANCE-DATETIME>20250908170259
ACCESSION NUMBER:		0000950170-25-113599
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250831
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250908
DATE AS OF CHANGE:		20250908

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYTOKINETICS INC
		CENTRAL INDEX KEY:			0001061983
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				943291317
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50633
		FILM NUMBER:		251300761

	BUSINESS ADDRESS:	
		STREET 1:		350 OYSTER POINT BOULEVARD
		STREET 2:		.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 624-3000

	MAIL ADDRESS:	
		STREET 1:		350 OYSTER POINT BOULEVARD
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>cytk-20250831.htm
<DESCRIPTION>8-K/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-09-08T17:01:21.5260+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:cytk="http://cytokinetics.com/20250831" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K/A</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_791ea97c-01e6-40e6-9bdb-f2749620ff26" name="dei:AmendmentFlag" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296">true</ix:nonNumeric><ix:nonNumeric id="F_8ed50108-0721-4cd7-9e25-34a4987a6afd" name="dei:EntityCentralIndexKey" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296">0001061983</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cytk-20250831.xsd"/></ix:references><ix:resources><xbrli:context id="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001061983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-31</xbrli:startDate><xbrli:endDate>2025-08-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6586939c-dbc3-4ecd-a969-9ede9f3a1d52" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K/A</span></ix:nonNumeric></span></h2><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_b33f7397-51cb-45b1-8131-c84db3ca6b07" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">August 31, 2025</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3ba222e-bf7e-4314-99fb-4bf05b419b87" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cytokinetics, Incorporated</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:41%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f9c0e7b5-ddf4-42e5-bdb2-0e5cf6011edb" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a0483d9d-cc5b-4e03-81b7-d374e5a59bb2" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">000-50633</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2284ea5f-8763-4994-aaea-81b242166d2d" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">94-3291317</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_288f1810-f7d2-48da-b85c-32909612a671" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">350 Oyster Point Boulevard</span></ix:nonNumeric></span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0c1eaa8c-2fc8-47fc-9fc7-50c0595b565d" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">South San Francisco</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_5348dc27-e025-4721-a6a5-d381fd724ff0" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_377a97a1-3424-4f94-ae59-5fc571da0cd2" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">94080</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_8cab2d56-f739-463e-a6ae-bcdab602240f" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(650)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_0e49bebf-d9bf-4317-8557-dc1cec86df50" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">624-3000</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_407f0230-0529-4fb7-8cd2-d2b790637509" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">n/a</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:3pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b45a4ed6-8c8a-4658-9f15-086e110db42a" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e4adb32e-9579-408e-a7e9-00355882692f" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2bc4eefb-e3a9-4396-8eb5-cc38ea7b9f98" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e906ad25-37c2-4904-b4c7-bbe27ac5eb80" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_59a82fe4-4d67-4126-bfb9-be1e14ff1e47" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.001 par value</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e3fc3cff-6cf7-42f0-b010-acee5e478527" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CYTK</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3281ab6e-cac9-40d7-a732-beb8a63bad7e" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_9457b223-7779-4ea3-8df8-38768e5d6813" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Explanatory Note</span></p><p style="font-size:10pt;margin-top:3.6pt;font-family:Times New Roman;margin-bottom:3.6pt;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c94f51a-7772-473e-8d18-5440addd850f" contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296" name="dei:AmendmentDescription"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"></span></ix:nonNumeric>&#160;</span></p><h2 style="font-size:10pt;margin-top:14.4pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8.01 Other Events.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 31, 2025, Cytokinetics, Incorporated announced that additional data related to aficamten were presented at the European Society of Cardiology Congress 2025 in Madrid, Spain, including a pre-specified analysis of the effect of aficamten on cardiac structure and function from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), which was simultaneously published in the Journal of the American College of Cardiology, as well as a Late Breaking Clinical Science presentation related to the incidence and impact of atrial fibrillation (AF) associated with aficamten, which was simultaneously published in Heart Rhythm. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Current Report on Form 8-K/A is being filed because the original Form 8-K filed on September 2, 2025 was missing a hyperlink to the press release that is furnished as Exhibit 99.1 to this Current Report on Form 8-K/A.</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99.1  </span><a href="cytk-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Press Release dated August 31, 2025</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104  The cover page of this report has been formatted in Inline XBRL</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CYTOKINETICS, INCORPORATED</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">September 8, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ John Faurescu</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SVP, Deputy General Counsel &amp; Secretary</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cytk-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2025-09-08T17:01:21.5771+00:00 --><!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img114956760_0.jpg" alt="img114956760_0.jpg" style="width:182px;height:79px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CYTOKINETICS PRESENTS NEW DATA RELATED TO </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">AFICAMTEN</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional Data from MAPLE-HCM Shows Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improves Cardiac Structure and Function Compared to Metoprolol;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Simultaneous Publication in the Journal of the American College of Cardiology</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Analysis Shows Annual Incidence Rate of Atrial Fibrillation with Aficamten is 1.5%,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Consistent with Expected Rates in Prediction Model of Patients with HCM;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Simultaneous Publication in Heart Rhythm</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Longer-Term Data Presented Consistent with Previously Reported Safety Profile of Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:30 AM Eastern Time</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SOUTH SAN FRANCISCO, Calif., Aug. 31, 2025 - </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data related to </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">were presented at the European Society of Cardiology Congress 2025 in Madrid, Spain, including a pre-specified analysis of the effect of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on cardiac structure and function from MAPLE-HCM (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">M</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">etoprolol</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vs </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">P</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">atients with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">L</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VOT Obstruction on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">E</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">xercise Capacity in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HCM</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), which was simultaneously published in the </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Journal of the American College of Cardiology</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as well as a Late Breaking Clinical Science presentation related to the incidence and impact of atrial fibrillation (AF) associated with </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which was</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">simultaneously published in </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Heart Rhythm</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;The echocardiographic results from MAPLE-HCM elaborate on the superiority of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compared to the current standard-of-care </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">metoprolol </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as was previously reported in the primary efficacy analyses,&#x201d; said Fady I. Malik, M.D., Ph.D., Cytokinetics&#x2019; Executive Vice President of Research &amp; Development. &#x201c;The additional data presented at the ESC Congress 2025 continue to strengthen the evidence base supporting the overall safety profile of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">including as has been observed with a real-world dosing strategy.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is an investigational drug candidate currently under regulatory review in the U.S; the Food and Drug Administration (FDA) is reviewing a New Drug Application (NDA) for </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with a Prescription Drug User Fee Act (PDUFA) target action date of December 26, 2025.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Analysis from MAPLE-HCM Assesses Effect of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Compared to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Metoprolol</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on Cardiac Structure and Function</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dr. Sheila Hegde, M.D., M.P.H, Assistant Professor, UT Southwestern Medical Center, Dallas, TX, Affiliate Faculty, Brigham and Women's Hospital, Boston, MA, presented a pre-specified</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">echocardiographic analysis assessing the effect of treatment with </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relative to </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">metoprolol</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on cardiac structure and function from MAPLE-HCM.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to primary results of MAPLE-HCM presented by Dr. Garcia Pavia at  the European Society of Cardiology Congress 2025, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was also shown to be superior to </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">metoprolol</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> at improving measures of diastolic function and reducing the likelihood of mitral valve systolic anterior motion (SAM) and mitral valve leaflet-septal contact, the primary contributor to left ventricular outflow tract (LVOT) obstruction (Figure 1) (all p&lt;0.001). There was a significant decrease in maximal wall thickness in patients treated with </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> compared to those treated with </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">metoprolol</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (treatment corrected difference = -1.01 mm [95% CI -1.8 to -0.2, p=0.015]) although the reduction in left ventricular mass index (LVMI) was not significantly different comparing </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">metoprolol</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. One (1.1%) patient treated with </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> experienced transient left ventricular ejection fraction (LVEF) &lt;50% without heart failure or treatment interruption. These data were simultaneously published in</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Journal of the American College of Cardiology.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img114956760_1.jpg" alt="img114956760_1.jpg" style="width:410px;height:306px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-Term Treatment with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Does Not Appear to Increase Risk of Atrial Fibrillation in Patients with Obstructive Hypertrophic Cardiomyopathy</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health &amp; Science University, presented a new analysis of the incidence and impact of AF in patients with obstructive hypertrophic cardiomyopathy (oHCM) in a Late Breaking Clinical Science Session outlining the experience of patients treated with </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the open-label study, FOREST-HCM (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ollow-up, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">O</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pen-Label, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">esearch </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">E</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">valuation of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">S</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ustained </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reatment with </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HCM</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). These results were also simultaneously published in </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Heart Rhythm</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Among 173 patients followed for &#x2265;48 weeks, 136 had no history of AF at baseline. Four (2.9%) patients developed new-onset AF during follow-up, with an incidence rate of 1.5% per year. This rate is consistent with expected rates from validated prediction models in patients with HCM, the HCM-AF (3.6% per year)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and in healthy individuals, CHARGE-AF (1.4% per year). Importantly, the clinical impact of new AF was minimal, with one patient experiencing LVEF &lt;50% at the time of the arrhythmia event, and none experiencing heart failure. In three of these patients, sinus rhythm was restored without the need for antiarrhythmic medications or an atrial fibrillation ablation procedure. One asymptomatic patient did not undergo an attempt to restore normal sinus rhythm. Of the 37 patients with history of AF at baseline, 10 experienced recurrent AF episodes (27.0%), none of which were associated with LVEF &lt;50% or heart failure. In patients experiencing AF, the improvement in symptoms and hemodynamics, and the safety profile of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was no different than the overall cohort studied. Consequently, the authors concluded that long-term treatment with </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> did not appear to increase the risk for AF, nor did the presence of AF negatively impact clinical outcomes.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New Data from FOREST-HCM on the Longer-Term Safety and Efficacy of Treatment with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Consistent with Previous Reports</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sara Saberi, M.D., M.S., Associate Professor of Internal Medicine, University of Michigan Health Frankel Cardiovascular Center, presented new data related to the safety and long-term use of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in FOREST-HCM.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FOREST-HCM, the open-label extension clinical study, enrolled 296 patients with oHCM from May 28, 2021, through the data cutoff of August 31, 2024. The total cumulative exposure to </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was 352 patient-years over a mean follow-up of 62 weeks and maximum follow-up of 170 weeks. Consistent with previously presented data from FOREST-HCM, this updated data set demonstrates that long-term treatment with </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is associated with early and sustained hemodynamic and clinical benefits, along with a low incidence of new-onset AF and LVEF &lt;50%.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treatment with </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> resulted in a significant reduction from baseline in site-read Valsalva LVOT-G by Week 12 (resting LVOT-G = -40 mmHg [-42, -39] and Valsalva LVOT-G = -56 mmHg [95% CI -58, -52]; p&lt;0.0001 for both), which was sustained through treatment up to three years with minimal reduction in mean LVEF.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-term treatment with </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was also associated with reduced symptom burden. At Week 12 (n= 283) and Week 96 (n=44), 69% and 93% of patients, respectively, reported &#x2265;1 New York Heart Association (NYHA) Functional Class improvement from baseline. Patients also experienced a mean increase in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) of 15 and 16 points (p&lt;0.0001), at each time point respectively. Significant improvements from baseline were also observed in NT-proBNP, a biomarker of cardiac wall stress and high-sensitivity cardiac troponin I (both p&lt;0.0001).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One patient (0.3%) terminated treatment due to a treatment emergent adverse event of ischemic colitis, determined not to be related to the treatment with </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Dose down-titration occurred in 10 (3.4%) patients based on site-read LVEF &lt;50%. None of the site-read instances of LVEF &lt;50% were corroborated by the core lab, and none were associated with a serious event of heart failure. New-onset AF occurred in 3 (1%) patients.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Updated Integrated Safety Analysis, Including MAPLE-HCM, Provides Additional Evidence on the Safety and Tolerability of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in oHCM</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A new integrated safety analysis from three clinical trials of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> presented by Dr. Masri provided additional safety and tolerability evidence. The analysis included data from the Phase 2 clinical trial, REDWOOD-HCM, two Phase 3 clinical trials, SEQUOIA-HCM and MAPLE-HCM, and the open-label extension clinical study, FOREST-HCM.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In this integrated safety analysis of 463 participants with oHCM and almost 700 patient-years of exposure, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was shown to be well-tolerated and had an adverse event profile similar to placebo. There remains a low incidence of LVEF &lt;50% over extended exposure, with no occurrences associated with a serious event of heart failure. A low incidence of new-onset atrial fibrillation (1.9%) was observed with </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, at a rate comparable to placebo (2%) and </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">metoprolol</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (3.4%). There were no permanent discontinuations related to treatment with </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor Webcast Information</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cytokinetics will host an investor webcast on September 2, 2025, at 8:30 AM Eastern Time to discuss the primary results from MAPLE-HCM and other data presented at the European Society of Cardiology Congress 2025. Interested parties can register online at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://cytokinetics-esc-2025.open-exchange.net/</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The live webcast will be available on the Investors &amp; Media section of the Cytokinetics website at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">www.cytokinetics.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A replay of the webcast will be archived on the Cytokinetics website for six months.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">About </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is an investigational selective, small molecule cardiac myosin inhibitor discovered following an extensive chemical optimization program that was conducted with careful attention to therapeutic index and pharmacokinetic properties.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was designed to reduce the number of active actin-myosin cross bridges during each cardiac cycle and consequently suppress the myocardial hypercontractility that is associated with HCM. In preclinical models, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reduced myocardial contractility by binding directly to cardiac myosin at a distinct and selective allosteric binding site, thereby preventing myosin from entering a force producing state.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development program for </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is assessing its potential as a treatment that improves exercise capacity as measured by peak oxygen uptake (pVO</font><font style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and relieves symptoms in patients with HCM. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was evaluated in SEQUOIA-HCM, a positive pivotal Phase 3 clinical trial in patients symptomatic obstructive hypertrophic cardiomyopathy (HCM). </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> received Breakthrough Therapy Designation for the treatment of symptomatic HCM from the U.S. Food &amp; Drug Administration (FDA) and for the treatment of symptomatic obstructive HCM from the National Medical Products Administration (NMPA) in China.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is also currently being evaluated in ACACIA-HCM, a Phase 3 clinical trial of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in patients with non-obstructive HCM; CEDAR-HCM, a clinical trial of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in a pediatric population</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with oHCM; and FOREST-HCM, an open-label extension clinical study of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in patients with HCM.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This communication contains a summary of new data related to the clinical development of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> presented at the European Society of Cardiology 2025 Congress. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is currently under regulatory review in the U.S, where the FDA is reviewing a New Drug Application (NDA) for </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with a Prescription Drug User Fee Act (PDUFA) target action date of December 26, 2025. Additionally, the European Medicines Agency (EMA) is reviewing a Marketing Authorization Application (MAA) for </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and The Center for Drug Evaluation (CDE) of the&#x202f;China National Medical Products Administration (NMPA) is reviewing an NDA for </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with Priority Review.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">About Hypertrophic Cardiomyopathy</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickening of cardiac muscle leads to the inside of the left ventricle becoming smaller and stiffer, and thus the ventricle becomes less able to relax and fill with blood. This ultimately limits the heart&#x2019;s pumping function, resulting in reduced exercise capacity and symptoms including chest pain, dizziness, shortness of breath, or fainting during physical activity. HCM is the most common monogenic inherited cardiovascular disorder, with approximately 280,000 patients diagnosed, however, there are an estimated 400,000-800,000 additional patients who remain undiagnosed in the U.S.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4,5,6</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Two-thirds of patients with HCM have obstructive HCM (oHCM), where the thickening of the cardiac muscle leads to left ventricular outflow tract (LVOT) obstruction, while one-third have non-obstructive HCM (nHCM), where blood flow isn&#x2019;t impacted, but the heart muscle is still thickened. People with HCM are at high risk of also developing cardiovascular complications including atrial fibrillation, stroke and mitral valve disease.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> People with HCM are at risk for potentially fatal ventricular arrhythmias and it is one of the leading causes of sudden cardiac death in younger people or athletes.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> A subset of patients with HCM are at high risk of progressive disease leading to dilated cardiomyopathy and heart failure necessitating cardiac transplantation.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">About Cytokinetics</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. In addition, Cytokinetics is developing </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">omecamtiv mecarbil</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ulacamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a cardiac myosin inhibitor with a mechanism of action distinct from </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional information about Cytokinetics, visit </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">www.cytokinetics.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and follow us on </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">X</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LinkedIn</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Facebook</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">YouTube</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the &#34;Act&#34;). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to any of our clinical trials, statements relating to the potential benefits of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or any of our other drug candidates, or our ability to obtain regulatory approval for </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in any jurisdiction by any particular date, if ever. Cytokinetics' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics' other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CYTOKINETICS&#174; and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contact:<br>Cytokinetics<br>Diane Weiser<br>Senior Vice President, Corporate Affairs<br>(415) 290-7757</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">References:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hegde, SM. Effect of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Compared with Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM. JACC. 2025. DOI: </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://www.jacc.org/doi/10.1016/j.jacc.2025.08.022</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rowin, EJ, et al. Low Incidence of Atrial Fibrillation in Patients with Obstructive HCM Treated with </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: An Analysis from the REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials. Heart Rhythm. 2025.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chuang C, Collibee S, Ashcraft L, et al. Discovery of </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Aficamten</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. J Med Chem. 2021;64(19):14142&#x2013;14152. https://doi.org/10.1021/acs.jmedchem.1c01290 </font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CVrg: Heart Failure 2020-2029, p 44; Maron et al. 2013 DOI: 10.1016/S0140-6736(12)60397-3; Maron et al 2018 10.1056/NEJMra1710575</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Symphony Health 2016-2021 Patient Claims Data DoF;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. Am J Cardiol. 2016; 15;117(10):1651-1654.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology and Circulation, 58, e212-260.</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hong Y, Su WW, Li X. Risk factors of sudden cardiac death in hypertrophic cardiomyopathy. Current Opinion in Cardiology. 2022 Jan 1;37(1):15-21</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img114956760_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img114956760_0.jpg
M_]C_X  02D9)1@ ! @$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "7 5H# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5-+U*REGL]0T[4+.>&[LKVTFFMKNVFBG@EDBD1SHU_/A_P $D/V_=).DZ/\
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M(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>XTF1HQ,WA\<_3R^C)P;EE;&8/CQ\9YDJ,JN#R+A#*\QS'&8R2?*H2S#$X?
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MSQ#JSV]SK^NW$9F%FNH7=M;6D*V>F0S26VEZ=:6UM96:27-SY,FI:CJM_?\
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MT_%3_P '?A'_ .8>OORBOQ'_ (D_^C-_T9K@[_PFQ?\ \U^7Y]V>=_8.3_\
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M-#=6=Y:S2V]S;RQS0R/&ZL4XRCI)-?UT>S^0XR4E>+N?G]^WO^WO_P ,0?\
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MN^AMM3T?5;2]TK5+2SU&SNK6%RA*/Q*W]>0HSC+X6GY=?N>I\/\ [>_[>_\
MPQ!_PJC_ (M1_P +._X6=_PG7_,]?\(7_8?_  A7_"'?]2=XL_M+^TO^$L_Z
MA_V/^S_^7K[5_HWT1^RC\>_^&GO@#X"^.7_"*?\ "$?\)Q_PE/\ Q2_]N_\
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M>SVM[XLU_P /6VMQZ%X@M/#DNLZMH]WIJ9I-NR3;\BVTE=NR75GUW17X1_\
M#]KX3?\ "?\ ]G?\*'^(G_"K?^AQ_P"$D\-?\)__ ,@7S_\ DFOE_P#"._\
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M_P!HG]K?5_ VL_#;_A)_A;X_\^ZT?POX.M-*6]^ &@:*JPQ>+-4\67L>B_\
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M5[:Q@UC1I;_]>?#7Q>_9V_:CMOB_\)?!WC?PU\6M)T70+#PO\4[/PO>ZC?\
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MWN;>>/3?$>C^)/#^B>D?'SX!_#/]I7X9ZW\*OBKHG]K>'=6VW5E>VK16VO\
MA77[:*>+2_%GA/5)8+G^R?$6D_:;A;:Y:WN;*^LKF_T/7+#5O#NK:QH]_P#F
M_P#LE?\ !+;QO^R)\8=-^*W@S]J#3];@ET^?PUXS\*:I\"TAM/%O@O4;[3K_
M %31(]4'Q9N[OP_J7VO2M.U+1M?L(9I-.U;3K,ZA8:WH4NK^'M7;E&</>=IQ
MT3UL_6R?_#Z[.P*,H2]U7A+=7^';77]-UOLC-_X+D?\ )IOP]_[.(\)_^JU^
M+=?1'_!*+_DP3X"?]U2_]71\1:]$_;D_9&_X;.^$WA[X7?\ "P?^%;?V#\1-
M)\??VY_PBG_"8?:_[+\->+?#W]D_V9_PDOA;R//_ .$I^V?;_P"T)O*^P_9_
ML<GVKS[?T3]E'X"?\,P_ 'P%\#?^$K_X3?\ X0?_ (2G_BJ/["_X1K^U/^$E
M\:>(_%__ "!/[9U_[%]B_M_^SO\ D+W?VG[)]K_<>?\ 9H9<E[-1OJI7MKM9
M_(:B_:.5M'&U]-[KYG\ZW_!<#_D[?P3_ -D \(?^I]\4*_JQK\I_VX/^"8__
M  V7\6]$^*?_  N[_A7']C_#_2/ O]A?\*V_X3#[3_96O^*-<_M3^T_^$^\+
M^3Y__"2?9?L/]G2^5]B\_P"V2?:?)@_5BB<DXP2>L4[[Z7L$8M3FVM)-6VUM
M<*_C/_X)1?\ )_?P$_[JE_ZI?XBU_9A7XS_LH_\ !(W_ (9A^/W@+XY?\-!?
M\)O_ ,(/_P )3_Q2_P#PJC_A&O[4_P"$E\%^(_"'_(;_ .%E:_\ 8OL7]O\
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M+IK*PLK4PVL)152G*=KO1=%HO7^O\R8PC#5+5]6[Z'IU%%%06%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img114956760_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img114956760_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '$ E\# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O\W7QAXM_:%_:N_P""O_\ P5,^"?Q*_P"#A#XS
M?\$KOA3\#OCKX\/PK@\<_M0^-_#?P]UZTD^(&J:+'X ^'_AG7_VK/@#X;T*W
M\,:;;PWJ:=X<FU.*VL9(XETJR@59F_TBJ_S\?V%_^";W[%__  4>_P""\_\
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MO^)M4\N2=#<_\)#X0\+;$#&+SF 4_P M_P#P5)_:_P#V6?VL?^"^G_!"2?\
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M%#;>&_#VF?'[Q)IUS:?#O2]4L9=3UW3;?QC^Z'QK_:6_9Q_9KTG3->_:+_:
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M^&:=#_X:E\!ZM\5=2L;0ZA:S6O@+X7?&.>'Q-;II$EF=0_XE$OZR_&O]I_\
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M?2'_  6F_P""V/PR_P""3GA/X9>'+#3/ WQ,_:*^,_B#1M/\,_#?7/B+X?T
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M)^H"]U6;6KK3+SP!JWA'6?$MU8S:I*E])/<>.)-8DO+>&\?56NS//, ?K_\
ML%?%GX!_'+]C+]FKXH?LMOXI_P"&>_$?PD\)P?">S\<ZKXDUSQKHOA/PY8KX
M6M/#/C#6O%_B+Q?XFU;Q1X5GT2X\-^(-1UGQ9XHO+W5M*N[A_$>N+(FIW7\O
MW[,W_*Z+_P %#_\ LSSP3_ZSO^PU7]>/P>^$'PU^ 'PL\ ?!/X.^$M.\"?"W
MX7>%='\%> _!^E/>36/A_P -:#:1V6FZ?%=:E=7VIWTD<,8:ZU'5+Z^U34KI
MY[[4KV[OKB>XD^$O O\ P2F_9X^'_P#P4Z^,W_!5[1O&7QGN?VB?CC\-M+^%
MOBSP9J?B+P/-\%M.\/Z1X,^%/@:VO/#OAVU^'5EXYM-8?2?@_P"&;B>XU+XC
M:O9-J-]KLT>GQ6USI]II@!_$O_P;[?L.?LD?M _\$8?^"LOQI^./P!^&WQ9^
M*'@[3/CQX?\  7C+Q_X>M/$VM?#>W\)_LOZ9XYT;5/AG=ZFL\OPZ\4)XGU(Z
ME>^+O!;:)XGU(:=HMI?ZM<66BZ;;VW](_P#P:7^*-?\ $?\ P1>^#5GK>J7F
MIP>$OBQ\=O"_AY+R>6X.EZ!'\0+[7(=+M6E9S'9P:EKNJ3V\"D10"Y:.)515
M4?;G[#'_  19_9:_X)^_LB_M(_L8?!KQ[\?O$WPN_:BD\=R^/]>^)OBGX=ZS
MX^T=OB%\,K'X4ZT/!VJ>%?A7X,\.Z>+7P[80WNEC6O"WB PZTTMQ=F]L673D
M^C_^"<__  3X^#'_  3'_9FT;]E3X"^)OB?XM^'FA^+/%OC&TUGXNZUX4U[Q
MG)J?C._34=4@N-1\&>"_ .AO803QA+"*+P[#<11$K<75T^' !^%__!:[2O\
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MMS:7NGZKX"T.S\*>#;6TN-*U"PT[5=+@U8ZQI]CK6F:1KEO9)K&CZ5?6??\
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M=7\;7]GJ_B?7/%=S)K^I>&/#7@_0KJY34=?O(8'T[PWI42V45M')#+.DMS,
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M,]K@Q-!)Y9]3_9 _X)R_\$_?BS_P:U_'W]K;XD_#/X=_$S]I_P 7? /]L_\
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MOAU_PO;_ ).3_P"&I/\ D9O^%5?\*_\ ^2@?\2?_ ))A_P B=_Q+_P#D-?\
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M_P#:[_Z)S^SA_P"$A\3?_GOT?\/W_P!KO_HG/[.'_A(?$W_Y[]?BE17\*_\
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MG+VB;<#P\ZQ-?#_5/85)4^>HU+E<%S6E225I)J]I2LY?NE=JHFW"WZO^&O\
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M'P[\(^*-0\,P^ [Z+QK-H>G3_3VJ_%OX):3=_P#!<K_@IM_P3B^%.G_L_?\
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MJ6HZ3HNO:-8+J\/VA]"T:QTF;7KJYTW3EU+4-*_T,:* /X:/V>/C?^R);_\
M!07]K3_@J+_P2O\ @KHGPD_X)M?L,?\ !*WXI> ?BE\5OAY\$]=^ 'P@_:0_
M:6TQU^+6B?#?0O!FJ^&_ TWB?QIH.EW_ (%/B/5?$'A.S\5_VEH>CS^(WGT+
MQ'\+]>\0_P!"W_!!#X'ZU\!?^"2'[%V@^+)+VZ\<?$;X;7G[0WCG4M50)KFI
M>)/VDO%.O?'*237@4CE_M?3]+\>:7H5TEU&E[ -)CMKY?MD,V?V!HH ****
M"BBB@ KY,_;E^ _B_P#:9_9:^*/P0\!ZCX;TGQ7XV_X0G^RM0\77FIV'AZW_
M .$;^(OA'Q=??VA=Z-H^OZE%YNFZ!>06GV;2;OS+Z6VBF\B!Y;F'ZSHKBS+
M8?-<NQ^5XM3EA,RP6*P&*C3DX3>'QE"IAZRA-7<)NG4DHR2O%V:V.[+,PQ.4
M9EE^:X-PCB\LQV$S#"RJ052FL3@L13Q-!S@[*<%5I1<H-I2C=/<_DT_X<0?M
M=_\ 11OV</\ PK_B;_\ .@H_X<0?M=_]%&_9P_\ "O\ B;_\Z"OZRZ*_)?\
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M>@V%OI6A^'_#^AZ5;VFEZ-H>C:9:6NFZ3I.FVMM8:=86UO9V=O#;PQQKMT4
M%%%% !7\L=]_P1)_:NN;>;68]?\ V:Q]K^,WQ9\=K\%7^+7Q\7PGHNB^/_@I
MI'PUT?6+;]I5/ADW[4GB/Q%I>N6\VI7O@GQ-XENO %UINBZ>EPVH?\)1XMTZ
M?^IRBN/%X&AC?9^W4G[)R<.5I:R<&[Z/F5X1O"5X/[49-1:Y,5@J&,Y/;*3]
MFVX\K2UDX-WNGS*\(WB[P?VHMJ-OY8]-_P""'/[5^G>)/AA)+\6/@%JMOH-I
M^QT-3^(DEYXFT;Q)\-7_ &?TD_X3/2?!_P &M$^#UM\#OCO:.;M8O"/B#]H7
M2M3\2>)$T*TG\73Z5<>*/%AN_P!F/^":W[*GQ$_8Y_9_\0?"+XFWW@;6_$5S
M\9OB9X[M_$_@/Q#XNU:P\4Z+XRU"RU'2]8UG0O$>@>&-$^'_ (BBB5]&U#P3
M\.-$L_ %M#I-GK]FUSXB\0^);N?]!**RPV5X3"5?;48S4U&<4Y3<URS:<OB3
M;=XJTVW.WN<W(E%9X;+<+A:BJT5-249Q7--R5IM.5^:[<KI>^VYV]WFY$HK,
MUK1=&\2:-JWAWQ%I.F:_X?U_3+_1==T+6K"UU31M:T;5+66QU/2=6TR^BGLM
M1TS4;*>>SO["\@FM;RUFEM[B*2&1T/SEX#_8@_8M^%G@[QC\//AC^R%^R_\
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MFC*ND:_!X)_L.+6-, L-16YM0(J]NHHH **** "BBB@ HHHH **** "BBB@
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M._/S7Y?8KEM;FEN?Z/%%?YP]%?&?\3*_]47_ .;'_P#@$^W_ .)7_P#JN/\
MS6O_ ,8#_1XHK_.'HH_XF5_ZHO\ \V/_ / (?\2O_P#5<?\ FM?_ (P'^CQ1
M7^</11_Q,K_U1?\ YL?_ . 0_P")7_\ JN/_ #6O_P 8#_1XHK_.'KQCX[_\
MB.G_ &&]/_\ 1-[7JY'](+^V<VP&5_ZH_5OKM=4?;_V][;V5XRES>R_L6ES_
M  VY?:0WW/E>-_ ;_4WA//>*/]:_[2_L7 SQOU'^POJ?UGEG"'LOK/\ ;&*]
MC?GOS_5ZMK6Y'>Z_TWZ*_P E>BOUO_6__J7?^7?_ -['\D_ZV?\ 4!_Y=?\
MWL?ZU%%?Y*]%'^M__4N_\N__ +V#_6S_ *@/_+K_ .]C_6HHK_)7HH_UO_ZE
MW_EW_P#>P?ZV?]0'_EU_]['^M117^2O11_K?_P!2[_R[_P#O8/\ 6S_J _\
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MW_#6&AD2?M">!/B.T/PY_9LT[;-I174_V4YK[5FCN?#$CKYOBOQEY9_K'O\
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M5.TN9R?*+_6'2_U/6TW;ZQK[LE'E_@VY[/G:O90U4G+W3_1GHK_/<U>XT/\
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M[7L]>,?'?_D1T_[#>G_^B;VOJN"/^2LR+_L.A_Z1,_*_&_\ Y-/QU_V(ZO\
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MM$^(I9)]8;6?$W[+]Y9>$];N+KQ7<>'XTM?&/@81>=?LU_\ $V^&GPR\.?\
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M[CP_&EKXQ\#"+E_%"6US\)+&VUZ/3KS0M*_9]_:7?X<6?C?3=6\>^"M"N?\
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M+E^-PYM5#X_:7J/]TD5]CR]E4TMIR^WBTN3=0YM5#^(JG[R7[IGM>K7&M_\
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MO?R[S_AY/C[%M_X1G['H7E_V=]F\S_BU.;CUK5M._P"+DZ]X+_LC/V/]H?\
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M_"+_ /#M"T_X3#_A9@^('_"$?9QKR?8/^&[_ "(?^'=OV3[#L_X5G_9&M_\
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MX(OO@[J.M'XI_LI>'_B#97/@OQYK'AK4/ ?[1'Q+\ ^%?$D6B0^U>/OV-/\
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M&)'7S?%?C+R_1-7N-#_M34M:-WX,_P"%43?M,?M)6^E>)#XX^(8_9?N=<?\
M92T);:T\,_M9B'_AM+Q7XSDFGTA-.\#>,M.C^'NI7ESX5LM7F6P\7^-S%YAX
MH2VN?A)8VVO1Z=>:%I7[/O[2[_#BS\;Z;JWCWP5H5S_PUFI,G[/?@/X<-#\1
M?V;-1W3:J6U+]JR:^TEI+GQ/*B^5XK\&B/W'5KC6_P#A?_BO6A=^,_\ A:\W
MQV_:>M]5\2#QS\/1^U!<Z&_[)06YM/$W[69A_P"&+O%?@R2&?5TU'P-X-TZ/
MXAZI:7/BJRTF9;_Q?X(,2CO#_N45N6^^ME#KS;^S>N)_BNRBT3'II_T"IKDO
MO9V<?M<V_LU_O'\;2UCC/#L.I1>)/@UIVH6_B*'QUJEI_P $R)OA[H^N^&/"
M?A_XUZWILB7YLKCX"? ?PS(_[.?[1/AV:.?1VT?Q-^U!>67BS7+>Z\*7/B"-
M+KQAXY$7&2)<W/@?XE6V@QZC>:[I7[.7[2S_ !'L_!.F:3X]\:Z%;?\ #6&A
MD2?M">!/B.T/PY_9LT[;-I174_V4YK[5FCN?#$CKYOBOQEY>[X)BTR+PWIFG
M:?!X=A\"ZI>?\$V9OB%H^A>&O%OA_P""FMZE(WBPWMQ\>_@1XFD?]HS]HGQ%
M+)/K#:SXF_9?O++PGK=Q=>*[CP_&EKXQ\#"+E_%"6US\)+&VUZ/3KS0M*_9]
M_:7?X<6?C?3=6\>^"M"N?^&LU)D_9[\!_#AH?B+^S9J.Z;52VI?M637VDM)<
M^)Y47RO%?@T1K[,G_P!.JKOS?]/HJ_M/_)76^UIATM&R7\%^GLZKO?3^-%7Y
M]W?X?;/X_P#=[=3RW]B3XH? ?X5ZK\3-3^*'B;XI^!/B%XK\/:%\/_A;\0?A
M[\-_ GQ*L?!&A>*];^S?&74=3T_QE\5OA)-H6M^)O 4#_#;2_$^EZUJB:/X/
M\=_$>>32/[9_X1S4]._4?XQ?$'PU\5/VK_VX?!?PQ^*O[#GQE^ 'Q(_:'^&?
MQ!USPM^U[\0K'X9^$H/&*3ZKHLOQH^ OC[PC\;_!6E^,]$^'^AW5_I?BJ[T?
MXJZ9XI\;^%==ET=?@_KMF9HD_..^_93^'-M\8_$'AJ.#XAMH]C\1/C+X(M_@
M\WQ!^%W_  G^DZ;\/_@;+\2]%\4:C^TW_8Z_LH^)<:]*(]8\*>%=9E\6:OHN
MB7FFZ'I5KK'B?PI>W/#>&OV:? VJ>&WDN?%GB+4+C5;S]DH'XB6&G7>A>&_A
M<GQ^;Q#_ ,)AI7B+X->(?#2_''XY7?AT6-O%H7B#X!:5KOAN[?1=2GBFUZW\
M5>#VFBC/$4:2H.E"4(U:EVIRA*7+2J\\9)\T'S1KVFYTVX1A&-=0BHM*E.O2
MIQH.E!QC4J7:G*$I<M.HYQDGS4VG&M:?/3;C&,8UU"*BU!_P4.^.'@?]H[]M
M'X_?&3X:W-W?^ ?%OBRQM_">J7NE2:%-K>B>%?#&A>#;/7TT6>."ZTJTU]/#
MW]LV&GWMII^H6EA?6T&H:7I=ZEQIUK];:O<:'_:FI:T;OP9_PJB;]IC]I*WT
MKQ(?''Q#'[+]SKC_ +*6A+;6GAG]K,0_\-I>*_&<DT^D)IW@;QEIT?P]U*\N
M?"MEJ\RV'B_QN8OCKQ!^SYX-M/A_HWB&WU[Q%X>U"W^&'Q?\<2Z[JJ1^--$^
M*NJ^ /CA)\-=&TSPOX)\":#<^/?@':7&A2BYU2Z_:)CT.VN-7T:[N[._L]/\
M2>%[&Y^Y]6N-;_X7_P"*]:%WXS_X6O-\=OVGK?5?$@\<_#T?M07.AO\ LE!;
MFT\3?M9F'_AB[Q7X,DAGU=-1\#>#=.C^(>J6ESXJLM)F6_\ %_@@Q*DJDJM6
MK54>>O7H5GRQYDW6G*HTHMW:;EI1>E:RE&4HPYFJ?M)5*U2HESUJU"K+EAS*
M]6<JC7*WS23YM*/_ "]2YHR<8*3XSP[#J47B3X-:=J%OXBA\=:I:?\$R)OA[
MH^N^&/"?A_XUZWILB7YLKCX"? ?PS(_[.?[1/AV:.?1VT?Q-^U!>67BS7+>Z
M\*7/B"-+KQAXY$7&2)<W/@?XE6V@QZC>:[I7[.7[2S_$>S\$Z9I/CWQKH5M_
MPUAH9$G[0G@3XCM#\.?V;-.VS:45U/\ 93FOM6:.Y\,2.OF^*_&7E[O@F+3(
MO#>F:=I\'AV'P+JEY_P39F^(6CZ%X:\6^'_@IK>I2-XL-[<?'OX$>)I'_:,_
M:)\12R3ZPVL^)OV7[RR\)ZW<77BNX\/QI:^,? PBY?Q0EM<_"2QMM>CTZ\T+
M2OV??VEW^'%GXWTW5O'O@K0KG_AK-29/V>_ ?PX:'XB_LV:CNFU4MJ7[5DU]
MI+27/B>5%\KQ7X-$>GV9/_IU5=^;_I]%7]I_Y*ZWVM,.EHV4_@OT]G5=[Z?Q
MHJ_/N[_#[9_'_N]NIZ?J]QH?]J:EK1N_!G_"J)OVF/VDK?2O$A\<?$,?LOW.
MN/\ LI:$MM:>&?VLQ#_PVEXK\9R33Z0FG>!O&6G1_#W4KRY\*V6KS+8>+_&Y
MBSO#L.I1>)/@UIVH6_B*'QUJEI_P3(F^'NCZ[X8\)^'_ (UZWILB7YLKCX"?
M ?PS(_[.?[1/AV:.?1VT?Q-^U!>67BS7+>Z\*7/B"-+KQAXY$79ZM<:W_P +
M_P#%>M"[\9_\+7F^.W[3UOJOB0>.?AZ/VH+G0W_9*"W-IXF_:S,/_#%WBOP9
M)#/JZ:CX&\&Z='\0]4M+GQ59:3,M_P"+_!!B\V\$Q:9%X;TS3M/@\.P^!=4O
M/^";,WQ"T?0O#7BWP_\ !36]2D;Q8;VX^/?P(\32/^T9^T3XBEDGUAM9\3?L
MOWEEX3UNXNO%=QX?C2U\8^!A%3W?_7VKTY?AHQZ?9Y=U';"?&[W9H_C\_:5?
ML\K]VC'IM'E_E?\ NGQ:W,*1+FY\#_$JVT&/4;S7=*_9R_:6?XCV?@G3-)\>
M^-="MO\ AK#0R)/VA/ GQ':'X<_LV:=MFTHKJ?[*<U]JS1W/AB1U\WQ7XR\O
MT35[C0_[4U+6C=^#/^%43?M,?M)6^E>)#XX^(8_9?N=<?]E+0EMK3PS^UF(?
M^&TO%?C.2:?2$T[P-XRTZ/X>ZE>7/A6RU>9;#Q?XW,7F'BA+:Y^$EC;:]'IU
MYH6E?L^_M+O\.+/QOINK>/?!6A7/_#6:DR?L]^ _APT/Q%_9LU'=-JI;4OVK
M)K[26DN?$\J+Y7BOP:(_<=6N-;_X7_XKUH7?C/\ X6O-\=OVGK?5?$@\<_#T
M?M07.AO^R4%N;3Q-^UF8?^&+O%?@R2&?5TU'P-X-TZ/XAZI:7/BJRTF9;_Q?
MX(,2CO#_ +E%;EOOK90Z\V_LWKB?XKLHM$QZ:?\ 0*FN2^]G9Q^US;^S7^\?
MQM+6.,\.PZE%XD^#6G:A;^(H?'6J6G_!,B;X>Z/KOACPGX?^->MZ;(E^;*X^
M GP'\,R/^SG^T3X=FCGT=M'\3?M07EEXLURWNO"ESX@C2Z\8>.1%QDB7-SX'
M^)5MH,>HWFNZ5^SE^TL_Q'L_!.F:3X]\:Z%;?\-8:&1)^T)X$^([0_#G]FS3
MMLVE%=3_ &4YK[5FCN?#$CKYOBOQEY>[X)BTR+PWIFG:?!X=A\"ZI>?\$V9O
MB%H^A>&O%OA_X*:WJ4C>+#>W'Q[^!'B:1_VC/VB?$4LD^L-K/B;]E^\LO">M
MW%UXKN/#\:6OC'P,(N7\4);7/PDL;;7H].O-"TK]GW]I=_AQ9^-]-U;Q[X*T
M*Y_X:S4F3]GOP'\.&A^(O[-FH[IM5+:E^U9-?:2TESXGE1?*\5^#1&OLR?\
MTZJN_-_T^BK^T_\ )76^UIATM&R7\%^GLZKO?3^-%7Y]W?X?;/X_]WMU/3]7
MN-#_ +4U+6C=^#/^%43?M,?M)6^E>)#XX^(8_9?N=<?]E+0EMK3PS^UF(?\
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M_P"(?G_J[;_S O\ ^.>C_B'Y_P"KMO\ S O_ ..>C_B"WB9_T37_ )F<@_\
MGJ'_ !''PN_Z*C_S"<1?_.D_G#KQCX[_ /(CI_V&]/\ _1-[7]4?_$/S_P!7
M;?\ F!?_ ,<]<9X[_P"#<K_A-M#71O\ AL;^S-M];WGVG_AGK[;GR$F3R_)_
MX7A:??\ .SO\WY=N-ISD>_PMX1^(66\0Y3CL;P_['"X;%QJUZO\ :V25.2"C
M-.7)2S*I4EJUI"$GY'P'BGXK< \1^'O%F1Y+GWUS-,SRJIAL#A?[+SK#^WKR
MJTI*'M\7EU##4[QC)\U:M3AI9RNT?QC45_6I_P 0M_\ U?-_YK+_ /E!T?\
M$+?_ -7S?^:R_P#Y0=?T3_J]G'_0'_Y<87_Y>?YW?V!FW_0)_P"5\-_\N/Y*
MZ*_K4_XA;_\ J^;_ ,UE_P#R@Z/^(6__ *OF_P#-9?\ \H.C_5[./^@/_P N
M,+_\O#^P,V_Z!/\ ROAO_EQ_)717]:G_ !"W_P#5\W_FLO\ ^4'1_P 0M_\
MU?-_YK+_ /E!T?ZO9Q_T!_\ EQA?_EX?V!FW_0)_Y7PW_P N/Y*Z*_K4_P"(
M6_\ ZOF_\UE__*#H_P"(6_\ ZOF_\UE__*#H_P!7LX_Z _\ RXPO_P O#^P,
MV_Z!/_*^&_\ EQ_)717]:G_$+?\ ]7S?^:R__E!T?\0M_P#U?-_YK+_^4'1_
MJ]G'_0'_ .7&%_\ EX?V!FW_ $"?^5\-_P#+C^2NBOZU/^(6_P#ZOF_\UE__
M "@Z/^(6_P#ZOF_\UE__ "@Z/]7LX_Z _P#RXPO_ ,O#^P,V_P"@3_ROAO\
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MO^&$?] \CR?L&_\ X:8_M<_V!_9?]H_8'_X4SMNO4/"=W]I_X0/Q']O^V_\
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M9*,=75NUS74+^]5=_K'+&S*_LC,.:_U=6YYO2M1M;V<8QT=6[]Y-0<O>J/\
MWA**3/YL]6F_LWX:Z]J/VC^Q_P#A*_V=_P!I>'^V/^$F_P"%"_\ "=X_:QL!
M]G_X7OY=Y_P\GQ]BV_\ ",_8]"\O^SOLWF?\6IS<>M:MIW_%R=>\%_V1G['^
MT/\ M,:C_P *X_X4<&_L[R?V3K"3^U_^'3/VO_BU7V?[#YO_  O'_A([C_A&
M?[,_MD6DG_"HMES^[EW_ ,$ )G\-7^BZ7^UU_8^IZ_\ #OXE_#_QAX@_X9]L
M/$/_  ED/Q$^+,'Q0%__ ,(UXO\ BWXB\(_#G^QA9V.@^5\#-#^$U_J/V/\
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M\?8MO_",_8]"\O\ L[[-YG_%J<W'])FD_P#!!>\T_P#L&^NOVN?[2\3^%/\
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MXC_M?^U/^$8\5^?Y'_"*?8_L']G0^;]O^T?;8_LOD7/C'_$0-_U:3_YGK_\
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MO?R[S_AY/C[%M_X1G['H7E_V=]F\S_BU.;CUK5M._P"+DZ]X+_LC/V/]H?\
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M_H__  BGA[XWZYXLA_LW[98:5K-UK/AO2-:_F<U:;^S?AKKVH_:/['_X2O\
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M\3>+OAG_ &N6OM;_ +8^.?A;X5V%A_9W]G*+]-7\.ZEK'6W?_!=+4K7Q+?\
M@G_AD?S/'6F?$3XF>"+[P?\ \-%^$T^S:;\./A/!\4IO%'_"T3X"/[.>I?VE
M&;_1_P#A%/#WQOUSQ9#_ &;]LL-*UFZUGPWI&M?S.:M-_9OPUU[4?M']C_\
M"5_L[_M+P_VQ_P )-_PH7_A.\?M8V ^S_P#"]_+O/^'D^/L6W_A&?L>A>7_9
MWV;S/^+4YN/6M6T[_BY.O>"_[(S]C_:'_:8U'_A7'_"C@W]G>3^R=82?VO\
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MA'[8,W@K7?V9M1M/$?A;P)HOP9^%6K:1<^'?BA\3-1M_B[K'B3XF?V[\)CX
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M.T/PY_9LT[;-I174_P!E.:^U9H[GPQ(Z^;XK\9>7T7A"+3H_#VE:=8P>'X?
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MP:T[4+?Q%#XZU2T_X)D3?#W1]=\,>$_#_P :];TV1+\V5Q\!/@/X9D?]G/\
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M_P K_P!T^+6YA2)<W/@?XE6V@QZC>:[I7[.7[2S_ !'L_!.F:3X]\:Z%;?\
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M^;_I]%7]I_Y*ZWVM,.EHV2_@OT]G5=[Z?QHJ_/N[_#[9_'_N]NIZ?J]QH?\
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M\7^"#%TQWA_W**W+??6RAUYM_9O7$_Q791:-X]-/^@5-<E][.SC]KFW]FO\
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MM07.AO\ LE!;FT\3?M9F'_AB[Q7X,DAGU=-1\#>#=.C^(>J6ESXJLM)F6_\
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MZ!\0-+^ /Q5^(W@2+2?#Z^$_'_Q(^&?BGQAH7_")^"FT[6K=O!/A,Z,>%O\
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M\)O6L]*]DCA]6F_LWX:Z]J/VC^Q_^$K_ &=_VEX?[8_X2;_A0O\ PG>/VL;
M?9_^%[^7>?\ #R?'V+;_ ,(S]CT+R_[.^S>9_P 6IS<>M:MIW_%R=>\%_P!D
M9^Q_M#_M,:C_ ,*X_P"%'!O[.\G]DZPD_M?_ (=,_:_^+5?9_L/F_P#"\?\
MA([C_A&?[,_MD6DG_"HMESY5(ES<^!_B5;:#'J-YKNE?LY?M+/\ $>S\$Z9I
M/CWQKH5M_P -8:&1)^T)X$^([0_#G]FS3MLVE%=3_93FOM6:.Y\,2.OF^*_&
M7E^B:O<:'_:FI:T;OP9_PJB;]IC]I*WTKQ(?''Q#'[+]SKC_ +*6A+;6GAG]
MK,0_\-I>*_&<DT^D)IW@;QEIT?P]U*\N?"MEJ\RV'B_QN8DK>YM:V%O=M*R=
MI-M>]RIZ5)KWJ<O<H^Y)BC;W=K6PV[E9)-<VJUC%/2I+XZ4[0I>Y<P_"=W]I
M_P"$#\1_;_MO_"+_ /#M"T_X3#_A9@^('_"$?9QKR?8/^&[_ "(?^'=OV3[#
ML_X5G_9&M_\ "$?V9_9QGE_X4]NN>2U:;^S?AKKVH_:/['_X2O\ 9W_:7A_M
MC_A)O^%"_P#"=X_:QL!]G_X7OY=Y_P /)\?8MO\ PC/V/0O+_L[[-YG_ !:G
M-QW'AV'4HO$GP:T[4+?Q%#XZU2T_X)D3?#W1]=\,>$_#_P :];TV1+\V5Q\!
M/@/X9D?]G/\ :)\.S1SZ.VC^)OVH+RR\6:Y;W7A2Y\01I=>,/'(BXR1+FY\#
M_$JVT&/4;S7=*_9R_:6?XCV?@G3-)\>^-="MO^&L-#(D_:$\"?$=H?AS^S9I
MVV;2BNI_LIS7VK-'<^&)'7S?%?C+RU]F6]_9U=++FO[6+MR_"I\NKA\$:?[Q
M?O62_A>]_9U5T4K^UBVOY>?EU<%[D:?[R/[T]5U;3O\ BY.O>"_[(S]C_:'_
M &F-1_X5Q_PHX-_9WD_LG6$G]K_\.F?M?_%JOL_V'S?^%X_\)'<?\(S_ &9_
M;(M)/^%1;+GDO"=W]I_X0/Q']O\ MO\ PB__  [0M/\ A,/^%F#X@?\ "$?9
MQKR?8/\ AN_R(?\ AW;]D^P[/^%9_P!D:W_PA']F?V<9Y?\ A3VZYW-7N-#_
M +4U+6C=^#/^%43?M,?M)6^E>)#XX^(8_9?N=<?]E+0EMK3PS^UF(?\ AM+Q
M7XSDFGTA-.\#>,M.C^'NI7ESX5LM7F6P\7^-S%G>'8=2B\2?!K3M0M_$4/CK
M5+3_ ()D3?#W1]=\,>$_#_QKUO39$OS97'P$^ _AF1_V<_VB?#LT<^CMH_B;
M]J"\LO%FN6]UX4N?$$:77C#QR(JZNUOXM3:[T=&/)9O5IO\ A7]ZN[JM:-B]
M.?2W\2=K7:UHQY+)ZR3?\)O6L]*]DC^A3_@@#:;/!WQ[U3[!Y?\ ;7_"+7?]
MN?\ "L_[-_X23ROCM^UW;?;_ /AHOSV_X:S\CR_L?_"S/L.G?\(WY7_""^1)
M_8GG/_1!7\ZG_!O]-IIT/]I6UCN/#K>(K*[\(P^++&W\3>++GQ_INI/\;?VM
MY+:W^*'PYNHQ\+?A-XBDL6@FT_PS\%I[GPGJ6BO9Z[JLB^(KW4$']%=?<Y-_
MR+,):WP2V;>OM)WO?K>_,E[JE=1]U(^UR?\ Y%N%M;X);-O7VD[[ZIWWBM(N
M\8^ZD%%%%>F>D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M ?RI_P#!Q+_R<E_P3Q_[(?\ M^_^I[_P3\K\,Z_OE\5_ O4?$G[77P._:/&L
M:8FA?"?]G']JCX(ZAX9N+2>75-5U;]H+XF_L<^.]&UVRNN;."P\/6?[,VO:?
MJ<$ZFYNKCQ1I4EJ1%:7@/T5]BL_^?2V_[\1?_$5^&\>^#+XWXAJYZN(UEGM,
M+A<-]5>4/&<OU:#CS^W_ +3PM^>[?+[)<MK<TKW7[UX>^-L>!.'*60/AEYI[
M/%XK%?6UG"P5_K,XRY/8?V7B[<G+;F]L^;^6)_G(45_HW_8K/_GTMO\ OQ%_
M\11]BL_^?2V_[\1?_$5\7_Q+7+_HLX_^(\__ )^>O]/3[C_B9^/_ $1$O_$D
M7_SA]?Z>G^<A17^C?]BL_P#GTMO^_$7_ ,11]BL_^?2V_P"_$7_Q%'_$M<O^
MBSC_ .(\_P#Y^>O]/0_XF?C_ -$1+_Q)%_\ .'U_IZ?YR%?.7[0__'CX7_Z^
M]4_]$V=?Z?GV*S_Y]+;_ +\1?_$4AL+%L;K.T;'3-O"<?3*5[O#?@)+A_.L%
MF[XJ6+^J?6/]G_L-T/:?6,)7PO\ %_M>MR\GMW/^'+FY.7W>;FC\-XD>-D?$
M'@O.>$%PT\H>;_V=_P *']L+'_5_J&:X#,_]T_LO!^U]K]2=#_>:?L_:*K[_
M ">SE_DPT5_K.?V=I_\ SXV?_@-!_P#$4?V=I_\ SXV?_@-!_P#$5^J?ZH/_
M *&"_P#"3_[Y]?Z>G\K?ZI_]1_\ Y:__ 'R?Y,=%?ZSG]G:?_P ^-G_X#0?_
M !%']G:?_P ^-G_X#0?_ !%'^J#_ .A@O_"3_P"^?7^GH?ZI_P#4?_Y:_P#W
MR?Y,=%?ZSG]G:?\ \^-G_P" T'_Q%']G:?\ \^-G_P" T'_Q%'^J#_Z&"_\
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M9_\ @-!_\11_9VG_ //C9_\ @-!_\11_J@_^A@O_  D_^^?7^GH?ZI_]1_\
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M$$$3^3'NC$>/+"-MR@CP-@4@+@;<8I!9V@+D6ML#*K+(1!$#(K$,RN0N75F
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MA&VY01X&P*0%P-N,4@L[0%R+6V!E5ED(@B!D5B&97(7+JS ,P;() )Y J?\
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MQ?D35U'FNY^^Y\O[M+_5WW>7ZXO@E#_=_=M*HJEN7V_P)JZC>_M/?<W'W#^
M?5KC6_\ A?\ XKUH7?C/_A:\WQV_:>M]5\2#QS\/1^U!<Z&_[)06YM/$W[69
MA_X8N\5^#)(9]734? W@W3H_B'JEI<^*K+29EO\ Q?X(,7FW@F+3(O#>F:=I
M\'AV'P+JEY_P39F^(6CZ%X:\6^'_ (*:WJ4C>+#>W'Q[^!'B:1_VC/VB?$4L
MD^L-K/B;]E^\LO">MW%UXKN/#\:6OC'P,(O]$#[%9;!']DM?+#%Q']GBV!R
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M5[)7;LE=MZA11172=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\2;/P]\&_AQ?:AX<U:U?6Y-?ML:9>"RUBP_H3K^5WP;_ ,$4?C]^W?\ %_\
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MT?XA?$#QUIOCI+7PIX!N/%SW?@;2DUZTT[Q_XR\8:1K&D?#SP%XP%A)<'O\
MP;_P7L_91^('Q&^.WPM\)? ?]NC4_%WPB_9KU7]KGX=:?/\ LPZWH][^U_\
ML_Z=K-MH-G\1?V1= USQ!IGBSXE>'/$^HWD \':YXH\/?#_0O%%DFH:KI.JW
M&EZ)KMYIGY;>&O\ @E3^W)XQ_P""8O@7]G#XJ? C3M/^-/\ P4#_ ."N=A^U
ME_P5(T9OB9\)]7MOAU\ =5^/U[\2_&-]>>)++QM<:7\3[W^Q_AM\*+C2/"7@
M6^\3WL]]X@U$SV]A=VFJ%?KGXR?L/_MR>/?VI_\ @M[^U/X3^%NE^'_&?CS_
M ()X^&_V&/\ @F=<7/CWX=PWWC70+[X<>*?%/Q.N+*2S\43P?#.>?XW'0/\
MA"8OB2OA#2[G56T^_P#$#:7X=TZ]U9@#6^#G_!QW\ O&7[+5W^U=\3/V9?VN
MOA_HWQ2_:.7X&_L3_!+2?@];^+OCQ^V?:ZE+;V.AWOP \,Z;XR.F_$C4[(VU
M_J/Q)U6TO_#WPX\!>)]5TCX*Z#XY^)'CY="O_'?T-IG_  7I_8QN_P!A#]I/
M]O;6O!7[2G@7PS^R+\2[7X.?M!_L[_$+X7:'X-_:I^'/Q0U'QUX7\ Z5X+UK
MX:ZUX[M_#46KZEJ7C#1M03/C];/3M/CUNTURZTKQ'X9\1Z!I7XT?$;_@F#^W
M[XB_9C_X(N_&71/V$[^W^,O_  3&\+_$OX'_ ! _8/\ #7_!0?3_ (+?$GXE
M^#_%'@GPMX!T?XZ^!_VS_@;K_P .='^%?CO4?$?A.Z^+'B;P]X;\:W+R6GB#
M3O#4]WKEO9>(?"VL=W<?\$@OVM?B)\!?V=_AUX^_93^%?@6X_:X_X*<_!O\
M:L_X*4>%/#W[1GQ=^/\ +X9_9=^#-OJ&KZ-\,_CQ\4?VL?VG_C#XH_:!^,7B
M:ZO8=&\:^*_@?;1>"[W5+: 6_A>[T?3D\1:P ?M%^R1_P66_9>_;%_:GUO\
M9&\$_#O]IWX9?$3_ (4Q;?M$?"[Q#\?/@M=?"GP'^T1\#KO6K70;7XJ? 74]
M6UZZ\0>,O M_?77F:'XFU/POX<T?Q786>J:EX1O->L=(U2>T_6JOQN^!7[*G
MQZU/_@M/^V[^W9\:?A\GAKX5Z+^R_P#L_P#[(W[&GBB[\5>#=>OO&_@*6^O?
MBU\=]7C\.^'_ !#K.N^"+?2_BZ$TRQA\7:=X?U'6K&^?4=.M9;:>_$7[(T %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU='_  _#_P""6W_1TUI_X:'X^?\ SJZ/[1R__H/P7_A50_\ EGFOO#^T<O\
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MK[/]A\W_ (7C_P )'<?\(S_9G]LBTD_X5%LN>2\)W?VG_A _$?V_[;_PB_\
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MVC^Q_P#A*_V=_P!I>'^V/^$F_P"%"_\ "=X_:QL!]G_X7OY=Y_P\GQ]BV_\
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M_P#%JOL_V'S?^%X_\)'<?\(S_9G]LBTD_P"%1;+GDO"=W]I_X0/Q']O^V_\
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M_P (O_P[0M/^$P_X68/B!_PA'V<:\GV#_AN_R(?^'=OV3[#L_P"%9_V1K?\
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M3W@WX<>%/&MKJ?P[U*XO/@_\,/%/CC6M0MM4TZ7X>V?C&#3?%[>%_HCX;?\
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M_P#8#0_]2&?QW],/_DFN#O\ L>8__P!0(G'4445^_'\!A1110 4444 %%%%
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M'\15/WDOW3/:]6N-;_X7_P"*]:%WXS_X6O-\=OVGK?5?$@\<_#T?M07.AO\
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MV'X:\7Z-K'V;1]1_:5T;Q)I6O_\ "QI_@=Y&FW?Q1MM4L=8_X6W=V;W7P?\
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M#_;'_"3?\*%_X3O'[6-@/L__  O?R[S_ (>3X^Q;?^$9^QZ%Y?\ 9WV;S/\
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MI^\HV4O>3"BBBO3/2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /Y4_P#@XE_Y.2_X)X_]D/\ V_?_ %/?^"?E?AG7[F?\'$O_ "<E_P $
M\?\ LA_[?O\ ZGO_  3\K\,Z_AWQY_Y.#B?^Q7EG_IJ9_>7T??\ DW.&_P"Q
MMFO_ *=IA1117XR?MP4444 %%%% !7P!\0O^1X\5?]AN_P#_ $<U??\ 7P!\
M0O\ D>/%7_8;O_\ T<U?L7@[_P C+.?^P&A_ZD,_COZ8?_)-<'?]CS'_ /J!
M$XZBBBOWX_@,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /N;]D![:2*TT^RDTZ;QK?\ [2_[*:>#M)T?4M6USXQ:I<IXZU5;J/X2
M_!+Q J?L_P#QEU&.XFTM-2TSX[7=KI.EW]QX:T_1V;3/%/C!H_6Y$N;GP/\
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MK??G^W\?VC[3)_\ D6X7_!+[/+O4F[VZWWY_M_']H****],](**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH _)']L+]G/X/?M.?\%'?V)?
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M (=$_P#!/S_HA=S_ .'4^,7_ ,WU?C)_P_A_:O\ ^B9?L\_^$W\2?_GIT?\
M#^']J_\ Z)E^SS_X3?Q)_P#GIU\E_K[X#_\ 1-95_P"(;@?_ )F\OS[L^Q_X
MAY](#_HJ<V_\37,/_FGR_/NS]F_^'1/_  3\_P"B%W/_ (=3XQ?_ #?4?\.B
M?^"?G_1"[G_PZGQB_P#F^K\9/^'\/[5__1,OV>?_  F_B3_\].C_ (?P_M7_
M /1,OV>?_";^)/\ \].C_7WP'_Z)K*O_ !#<#_\ ,WE^?=A_Q#SZ0'_14YM_
MXFN8?_-/E^?=G[-_\.B?^"?G_1"[G_PZGQB_^;ZC_AT3_P $_/\ HA=S_P"'
M4^,7_P WU?C)_P /X?VK_P#HF7[//_A-_$G_ .>G1_P_A_:O_P"B9?L\_P#A
M-_$G_P">G1_K[X#_ /1-95_XAN!_^9O+\^[#_B'GT@/^BIS;_P 37,/_ )I\
MOS[L_9O_ (=$_P#!/S_HA=S_ .'4^,7_ ,WU>>ZC_P $-O\ @F%JU]=ZE?\
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MJ_\ Z)E^SS_X3?Q)_P#GIT?\/X?VK_\ HF7[//\ X3?Q)_\ GIT?\1E\+/\
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M>_Z(]^RK_P"$C\7/_GTT?VGPS_T!T/\ PWT__D/+\^[#^T^'/^@.C_X04O\
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MQ[U3[!Y?]M?\(M=_VY_PK/\ LW_A)/*^.W[7=M]O_P"&B_/;_AK/R/+^Q_\
M"S/L.G?\(WY7_""^1)_8GG/_ $05][DW_(LPE[_PWNT]/:3MMLK;1>L5:,O>
M3/N,H_Y%N$O?^&]VGISSM9KI:W*G[RC92]Y,****],](**** "BBB@ HHHH
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MQ[XJB^(5M\(?C3^V=^U9^S3XW^&'Q*U__@G)\//V<?!/@?X0WGQS\.^%=/\
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M]H;_ ,,M\2?_ )FJ_'_[%SG_ *%.9_\ A!BO_E1^T?VYDG_0XRK_ ,.&$_\
MEWFOO/GFBOH;_AD7]J__ *-A_:&_\,M\2?\ YFJ/^&1?VK_^C8?VAO\ PRWQ
M)_\ F:H_L7.?^A3F?_A!BO\ Y4']N9)_T.,J_P##AA/_ )=YK[SYYHKZ&_X9
M%_:O_P"C8?VAO_#+?$G_ .9JC_AD7]J__HV']H;_ ,,M\2?_ )FJ/[%SG_H4
MYG_X08K_ .5!_;F2?]#C*O\ PX83_P"7>:^\^>:*^AO^&1?VK_\ HV']H;_P
MRWQ)_P#F:H_X9%_:O_Z-A_:&_P##+?$G_P"9JC^Q<Y_Z%.9_^$&*_P#E0?VY
MDG_0XRK_ ,.&$_\ EWFOO/GFBOH;_AD7]J__ *-A_:&_\,M\2?\ YFJ/^&1?
MVK_^C8?VAO\ PRWQ)_\ F:H_L7.?^A3F?_A!BO\ Y4']N9)_T.,J_P##AA/_
M )=YK[SYYHKZ&_X9%_:O_P"C8?VAO_#+?$G_ .9JC_AD7]J__HV']H;_ ,,M
M\2?_ )FJ/[%SG_H4YG_X08K_ .5!_;F2?]#C*O\ PX83_P"7>:^\^>:*^AO^
M&1?VK_\ HV']H;_PRWQ)_P#F:H_X9%_:O_Z-A_:&_P##+?$G_P"9JC^Q<Y_Z
M%.9_^$&*_P#E0?VYDG_0XRK_ ,.&$_\ EWFOO/GFBOH;_AD7]J__ *-A_:&_
M\,M\2?\ YFJ/^&1?VK_^C8?VAO\ PRWQ)_\ F:H_L7.?^A3F?_A!BO\ Y4']
MN9)_T.,J_P##AA/_ )=YK[SY>\3?\BYX@_[ FJ_^D%Q7YU5^SWB']D']K.;0
M-<BB_9>_:)EEET?4XXHH_@G\2GDDD>RG5(XT7PR6=W8A55069B  20*^"O\
MAA7]MW_HSC]JG_Q'KXN?_,A7[QX1Y?C\/EN;1KX'&4)2QU%Q5;#5J;DEATFT
MIPBVD]+K2Y_"7TN,1A\PXAX0G@*]''0IY+CXU)8.K#$QIRECH.,9RHRFHR:U
M2DTVM5H?*U%?5/\ PPK^V[_T9Q^U3_XCU\7/_F0H_P"&%?VW?^C./VJ?_$>O
MBY_\R%?K?U?$?\^*W_@J?_R)_(WU?$?\^*W_ (*G_P#(GRM17U3_ ,,*_MN_
M]&<?M4_^(]?%S_YD*/\ AA7]MW_HSC]JG_Q'KXN?_,A1]7Q'_/BM_P""I_\
MR(?5\1_SXK?^"I__ ")\K45]4_\ #"O[;O\ T9Q^U3_XCU\7/_F0H_X85_;=
M_P"C./VJ?_$>OBY_\R%'U?$?\^*W_@J?_P B'U?$?\^*W_@J?_R)\K45]4_\
M,*_MN_\ 1G'[5/\ XCU\7/\ YD*/^&%?VW?^C./VJ?\ Q'KXN?\ S(4?5\1_
MSXK?^"I__(A]7Q'_ #XK?^"I_P#R)\K45]4_\,*_MN_]&<?M4_\ B/7Q<_\
MF0H_X85_;=_Z,X_:I_\ $>OBY_\ ,A1]7Q'_ #XK?^"I_P#R(?5\1_SXK?\
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MPK^V[_T9Q^U3_P"(]?%S_P"9"C_AA7]MW_HSC]JG_P 1Z^+G_P R%'U?$?\
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M_P""I_\ R(?5\1_SXK?^"I__ ")C_ #4?L'AG]I)/[7_ +*_M'X!:UIWE_\
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M/B/Q_';<SX9_98_:J+^!]=N_V;OVEEOO"@_X)YVUOJ&L_L^ZGH7Q*T6+P/\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cytk-20250831.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-09-08T17:01:21.9632+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://cytokinetics.com/20250831" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:cytk="http://cytokinetics.com/20250831" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cytk-20250831.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentDescription" order="10450.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 31,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cytokinetics, Incorporated<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001061983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3291317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">350 Oyster Point Boulevard<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">624-3000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">n/a<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CYTK<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cytk-20250831.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K/A" isOnlyDei="true" isUsgaap="true" original="cytk-20250831.htm">cytk-20250831.htm</File>
    <File>cytk-20250831.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cytk-20250831.htm": {
   "nsprefix": "cytk",
   "nsuri": "http://cytokinetics.com/20250831",
   "dts": {
    "inline": {
     "local": [
      "cytk-20250831.htm"
     ]
    },
    "schema": {
     "local": [
      "cytk-20250831.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_a19ad6a3-6969-42d7-9e74-94a197fa7296",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cytk-20250831.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a19ad6a3-6969-42d7-9e74-94a197fa7296",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cytk-20250831.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cytokinetics.com/20250831/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-25-113599-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-113599-xbrl.zip
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ME,4VJW)W@HR/2%Z,$OBX,6!<<G[+&UQO]YDXC],6&Q;9/^+^(!,(>[']-PX
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M-:E8&@^11H]CW><X>WLZ1C;[^L(57LFZEEG?B<Q:\?GI_6LDF905F1B1HZR
M1_*DV7 >!4V9_A%7<3QUZ8D5^E9DZTS:/0:U7!/0[M$]:EN6AJXL]^S%=]>-
M[Q_>@SP4\4!2UJN)D'OLH"=>U&@UYMT"\F86R7<*Z!.OH>G5Z;?[\AJH?.SM
M3%\A^$+1G]?"XC@EMRYQVB+W7]*")D6*5D,H+9 >*X@, 4D:1WN"LX(1)43+
M/01,GJ_:E\N;KT  6A:02\;&(HK2@!B*;  (0#<+8RC47H$V&B$Q G$^(NTL
M/5>G0,@F2;_YD'$1\RW2': HE]94O8>7R;(1J_H"%)1=R2B/\]I2@2B"TOF]
M:1):,Z&LBX6(OQB&Q1";B$80B;!SRMB)1-8GA[LG7_?IK^U#LGD(..0"VY:0
M2_34QR5ARTY0;T@"*HVNK_\^/B/'05FLVA^1RL,K1(CV%W90KL[!SF(V+/;#
M5C45=84FWZU-%P.T2^*\5P8-9#]^RX9" EVO!U+<C/BULR2!<YC&;TM&':X@
M2>1?1KY*N_,7J7HE8FW4RS*^1[J(O-QQ5 U.N9]C8@QE/?( #JY227QB-&8K
M, NUS#>* Q$G29EU<_?@ U:8XXBJ(DHKM,;JH9W]%="2(*>]4='K-XB,:$5#
M[(BZ4[SJ_$"1!K84&*(:RQ5^*BO2=5I9JZIN%<ZH:5:M;\/G"'$L*V,R0-*+
M@[@@OM_0RRYCBO90")FXNCA.GM!<;9AI/*N%NL+6YWN1AV??'O_FKJ2@ "0;
M17&"-!1 R&KW+!,Q]A&Y8G)_%::1$X4P0*T3H+8Q2C&KV$ = *YD6&^$?ASR
MY47-=],DKJ3M@K3;W&T\6NO/N[SW;>E\7^K\@[$+K$Z-ZRO1+65;!><[-004
M$8T=>21((4W@<%1<4+CV_3_U1J_HW]_6*/K&UG$.876/0$LM&Y9^8;4ZY;E6
M-2/OG%:\PY4NNN^J2K8:\+^J8GFM3NN:192"#[-+E(PR0#">A"AO957!L #0
MT"JCQD5UPYT*+9 _?CG]N@Z1K&J(Y#$D6NW!?CM1DF[G\]'NV>^G^]UG9-R[
MJ*P2]T[>#UZ&L/\:(G>5"O5A4Y%;LV+??(@>@3*J^)0HP&H"5!L(0VE2H:K&
M%SV61#*D+@M2RJ5*@(X]#%/,HXI#[NJA=?8W\$E!N[J;*)RG;%.PGI+I*7GF
MM^X-+YY<+_U9@[8&[8V#9C4>=Q-TF7Y)BO:A*Q^/OW2.]L\Z[>X6Z1RUCT]/
MCD]WS_;WGN4NJK40_5Y(>PW:&K0U:-_'1IWG469+B_<\[.9H='=:;X":5QO%
MF_D![U: <HWHTQ#]9?2"ASJOVA;/[V$ FWF3_);U4G+ A@+R</@^I?\;T<)K
MT-:@O4O0&N[C#BM::DS_8;;%OT^VR!X,AL6(?(84!$M(.QNF.23D)]8?;,LP
MO8""B=$*G.>\:BM?UI.*;W52<:$KE=:$M1AA[32#C(\^_;#3[!7]Y-/_ U!+
M P04    " !<B"A;IK);P],(  !C90  $0   &-Y=&LM,C R-3 X,S$N>'-D
M[5U;;]LV&'W?K^"TEQ:K+-E9U\:H,WA),QA+FR!.L6+#4,@2[1"528^B$OO?
MCZ1$W4S)CAU+=N"^Q*$^GN\<\2+JA'0__#:?^N !T@ 1W#/:+=L $+O$0WC2
M,[X,S?[P?# P?CO[X<./I@DN+@>?P6?X"/HN0P_P @6N3X*00O!J^.DU^/K[
M[148NO=PZH +XH93B!DPP3UCLZYE/3X^MKPQP@'Q0\;3!2V73"U@FC'X.86.
M* <7#H.@V[$[;TW[U+3?W[7?=>UVM]-NG?YZTOG9MKNVG:E&9@N*)O<,O')?
M U&+Y\88^CY<@$N$'>PBQP=#E?4-&&"W!?J^#VY%M0#<P@#2!^BU(M!YX'6#
M2 1SZ 2RS\X4!C/'A3TCEN(N&/F.,&3(C52(M/;[D[8!',8H&H4,7A(ZO8!C
M)_19SPCQ?Z'CHS&"'K_!/A1W)A>0N<Q;! ==B,-I)TDX'U&_1>A$)+(M.&<0
M!VCD0U.$02KO6V!V1/-%U3G#[^O0C:*YY"18--/C29S,;EM?/UU%3:J"?82_
MYZ(SY.P32UP>.0%4X6%@3AQGEM08.\%(1L<7)!D5[$&4UQQ MS4A#Q:_D L4
M%SVFNS_V6RNZF U%%81YCV2\DR2$YTL"X]O1/CT]M>15X^P' &1'0=,9H0Q$
M_>6*N+(E*I*)WTR5T11%9KMCGK1;',P >*FG5="UMB.AVFDC$DDC;TI"-9+(
M_K8LK[95U\H8J-K:WF9!GP6JQ!0E90STG?5I%(I=6'RH3*KO^&E2!V/"9"91
MI IG,X3')"KA9:*%NI3X\&XQ@T!\^'([6#TC6,R9$TRF"TM4L=0LKG[VL?<1
M,\06 YZ+3B4) R ^>]SR\&]KA2N*BJ0'^4,!23EM6_SCCXS,TR/YR,% A 8R
M<!^L(D@!/@R@=XW/Y.<9Y5,]CN[=%2^(*\<A%15=QW=#_^GU4EJEU>)"U53Y
M!E3C3-YB/YYXBBU\"\<[;F YZ77O*1SW#/%D,16:Z,(_K=_T,1#C.GM&P >/
M'\\@.<W."/KB=L71@F?%5"1ER$E9H2,F*B0P^:SRV>GQYVR:-DE,W%RH+\8S
MH7GYZP_MG_@OW\X)7USU1P&CCLL4DJ36,Y:O6_60ZO,&\F1CP<"E:)9MFPPW
M;5C=%"]]9U+%35ZOB=0Y[\Y]ODH])Q[4M67V<DV4U'"[@101/N(\L7C6<-/'
MU4Q2S&\5W.3EFBA%<U/?\_@3(8A_\,D"MC7\RF.;("MZV36](X^Z(5L6V031
M&\(7JO[?:%8R7"J"FZ [Y,L">$UO*'E T=M )>%B>*V4S_EHH8X_X ^R^9]P
M4<JU&%<KR8_\Q72"\.0/2A[9_3F9SAQ<3E4?72OA2^3#S^%T!&DIRTQ(K=0&
MV"64OVK(993L>N<DY&V[J!Q;U;5J%I"L H7O >D5G#C^-;V%$Q0P2*$G7)8*
M)6M5KU52E)LZF%52+X352O'.F0\\/@>@,8I>35=T[[+XFDB+%VC_YI[@\F&X
M%%(3M1O*Q\Z4KU)<Z=T-@B"$]$Z\2=#K\5A+=6659J@_B70#=(?0#2GOB^W.
MZ$Z\R6E(+H743.WCW+UW\ 26C'MM6%T4B8]<Q/B#]!.?[BER?!W!Y:":Z-U1
M1_QI8;B8CHB.6?YZ3:3^XHW%(!;]/L3QQ!=HR.GC="1%'>$F\T_B[R@0FU^&
M>1N"+R%)2+7+S)PE\,T?)?=I+2-$X!AG$@/\HU#^C4TF>?6Y^>IL@@UI)U @
M@U4+=V$C;$U:@.R2;=9@V+1C"/M48  !LDNR6L=A0]:)!QR! 8XF_TI8!W_A
M2FQ+6V#LDFNI0[$A\=AFCY'>J ] 8()K7)^6U,)X)B6R_Q,*!&1M*G+FQC,)
MB3 !!]WY2*[R/9Y)C405[:)P=Z^GX(UL)R0& Q(-<+C=\]<:)MNI4) @P@0Q
MZ.ZUI+;*=@($#HB =D^ZTEW93D<..C,ZX@0UC?CU3)=ME28YWH H"Y!IA-PT
M$1"9=J\X[]5LIRS%JHE\B7FSG0H."O*H-8ROHLFSH00) R1.#:17V3T;BN"P
MIIO!!1$PB)"!A*Y1U@X$U:6DZ!IMR%_6!60,VIU7H]= H=;!/&LH;<A>00&%
MM?/):=ELVI1Z @04TBYYYZRH3?M*A $BD%VRU7I3&[*.L4 >; WV?9HWYQSJ
MJO3\XPH&<83E$CXQS)@9D8FKCRF9ZC;,J'2DS#HK<^?JH%JUS48Q+C7/]H)X
M=O/-$N/$,FN2JFY+3M(;BG99DT0K-^HHQN6>V3Y0SV[?*3).7+(FB:[<U*-8
M5_ME>R-A>:N/5D#!)-L;^MH-0%H%RP;9WH@HV1:DE:'SQIH74K)9**] YX8U
M3[UR"U%>0+D=UKR,Y8U%>>X%^ZMYPFMM-\IK6.V&[8.LIVQ"*NI;VPQK7JA^
M:U)>D,;K:I[XB@U+>055AE>34LJV,2GV6GNK2<+K;FY2 M:RNO9(T/I2]DE$
MV48H15WK9^T#8=WVJ"+I)2NK4>*EFZ82VGH3JTG2VJU4BN^R>=4DU<H-5HIR
MN8.5/2&6,:'X"]OWXMFQX@$_G?FUBZ-Q\9FS8OJ\?7<\>G8\>K9Q8QZ/GAV/
MGAV/GJU)]'CT['CT['CT['CT['CT['CT['CT['CT['CTK Z*QZ-GS1\]RSH0
MSV+MS!S*\4SW'OG>$W?CZ-_U">7#NF>T[5_>VN+[ZF;\K5!TV9[1,4 8<$Y$
M1NI[QE[JBXR"1)C=/G!A>;,AT=4^.7!=)8Y%VG"=%R(P<CM27?:!ZZJP3%*1
MIR])9-9J20?@BVK'@DF3JCST45CM[:0Z#_TQ46((I2/REQ<AL,1,2F4>^CIF
MV8)*M?WZ(K2M\+!2N>]>B-SU'*]T*GH97;AHBZ7M>N@KUQ6>6BKT_8$+7?;A
MTDYZZ(^3U49>JO70%[-5SE^J\M![Z[)AF&CK'/KJ3N\X)OI.#GTTZNS*M&<>
M^D*@X':FW?+07ZY*'-.TY9ZR8HVWDQ6W;:D M=L,15_"'A5_L I?MQ\79+Z4
M/RJ)_E. L_\!4$L#!!0    ( %R(*%LG=%4)?R4  /,] 0 /    8WET:RUE
M>#DY7S$N:'1M[7UK<]M&LO;W_15SLN4-62])D=3-$IU4,205R;$N*]+QNDYM
MO34$AN1$  :+ 20SO_YT]PPNI"ZQ94D&UT@ED2@"@\%,=T]?GNY^\S_-)AL>
MG9RQOA/+:S&4VO&43B+!:N/3.CN>G+YC0^4DO@ABUF2+. X/M[9N;FY:[DP&
M6GE)+%6@6X[RMUBS^?,;'' 0"8Y_9D,>"W;8;7=WF^V#9OOUI+-_V.X<=CNM
MW?W]SO]KMP_;[?PN%2XC.5_$K.;4&=X$3PX"X7EBR8YDP -'<H^-TV<VV$G@
MM%C?\]@EWJ;9I= BNA9N"\?\VYM%['L__XV]60CNPD_V)I:Q)WX>_:MY<-#J
MO-DR'^&"+7O%FZERETS'2T_\]$/(75<&\\/7X:>>SZ.Y# YY$JO_D7ZHHI@'
M<>_/I@Q<\>FPW6O>B.F5C)NQ^!0WM?Q3-+G[1Z+CPTZ[_:H7*BUQQH>1\#BN
M<N\'FHXKK].'I4-U>[X,F@N![W/8D<&=][[9@CNS$1R/:_W3#SZ'&QT5Q+!1
M]!,^B^B']0?LWCUBF%XW@SOI#6#J86Q?O!FK$-Z2OIMQ7WK+PXGTA69GXH9=
M*I\'Z853%<?*AVMI);@GY\&A S,2$3Y%^G.F(^>G'^"73F?G8'=O?Z_]_]NM
M/\+Y#XQ[\=U?V)G=2#=>''9>=V$_[ +M'\#ON![A2[T!#I!-:"%CT=0A=\1A
M&(GF3<3#7N'I77CZ0P^D[ZY$%""5!2H0M/?F-6<R3C<3'ON/OW?VVKTW6WC'
MMWI;1WDJ.OQ[F_[IW?_N-V9KILISGV<Q!A\GY[^=G(TF)X,QN[@<C4=GDS$[
M&WU@P_ZDSRY'[_J3T9!-SEFZ8"_]&O2H0QG#<CI?\&+]HY-!_W0R.OM6\_ZL
M6;**#,UN3=CD>,1&[R_/+T;],S8^'YR,)A_9^1$;]"^')^?OSG_]R ;G9[\"
MB8[I./NV*_=7XJKS78JK+WCWQ[(UJ!%XWH+J NH09[-(^>RT?_%NU#P>G++Q
M0MUHUI])A_MPQ]?P_O._RX8P__,OQ(D?1NH:AAOPR)7<8>,X2IP8]68>N.PH
M"1Q2@ ?*#WDD7!8K=BI@22)X!:]7[?)&[/)8^HD'JKY0B687R13N-G:-#%B\
M$.RM2B+D:S6CCWU?1' %[CK8+'.!?R?Z@!>:+ROIO]$D]&6<4TYZQE'Z0+!+
M+75Z\ 1! A0,EK1T1> (=HDF.Q!N/X[0VCZ2TTAZGB'[&QDO\J.*P2!@R+]J
ME/NE*VF6&DXJ@'W'#V8C1Y]"X<1P-N&6:Y1I%W!227-PG2I7D&"[@*V'6[2Y
M!S26ZO#:C.U^Z/ Z%CR*V>5B&2_\ZESZ'JGCG0KF(FI.1.0;LP1X7^.<7;8N
M)^";:PE$Y"W9I4#?)UPSYC,1+^$K-9.>.2\J"Z8B]]*2.]EAP1+-L&.E8]!W
MP'B+5<1&UTCG:+-]$%.'PU>31&B7+]E8A+'PIR)BW0:Y;QJ,Q^SUX7:;]4_9
M""Z%!S.<Y$LM,D84Y&SYO=#4/:_[E1[ IUN-\?G[R3$;]\_8T67_;' R'IPW
MP-[SY*S58/UDWF+;'4,YK/E2AL'G,<,R5E<R$+%T3!!-12#6.<KUVAD'XO_/
M(1M\G/Q6!W9!3N!!H!*P#5RP<H$%>.[0<O'DH#B2<7&46_;SS'(ITV[<B$BP
M,#M]88'1ES!*(A4*'K"Q<B0>M2N^!#RCYW"+-N0%&MTI=R/I-M@XY#)HP%\<
M+\'P)>,X-KR(<.1,XOBI_6>=%F(V RL /U6;]^6;!^JT8SV >L4#.$L]@&ON
MWMHS!'>><]E/RTT5F4NU3$3!KO5SQ!Z?-4A1[FU^8=OB\W99?ITH>G;]Y*),
MJ[7B12KULKTKT[+]?CYAYU-SM.!IHDI.<Z,R+=XG$3E2"]";X&$2=*BR<RPH
M"&5:OWJ#P<.<!;OAFNF".]%;LA =BGH!"J6-A97[ 'E4I.X+7^5:1&!1<<^:
MKSH)151XO_W6]OZ3;4VG3'328$ ?-\+S\"=G[S""]$LD^!7:'P-/!K@J; QV
M# :8K*EC?-$%VQ'W169A*-2AI0^3)].$FV#4K!B,JO6/ZO! #?81#?'5)\L+
MVC"-4ADQ&9.7>_5*M68/B<-R+^-=L9\RK&AK \1NMW+UEM'5^_0O_ZG;[CB]
M"?K'G(4B%X^:P_- 4L*9I8'U];IG!TZR*7E144G'PXPH4:I(&N]=N:5".=UK
M3@$^ATOJ)%$D:%J@'\"F--6L"9M3=NW3S]Q4I5I=U-K@OS"/[T9I?-<J]6$D
M@6N7Z"0&\G"6UGLL=,.PB-MCFDN7'7%WR4Y:[!06YJK!3EO#5H-=+.A',=I@
M[CKHL=$GX228?,)^EZ#M8? 9%3]2]C"+AT>@D?R#^V&/#<6U\%2("4@M5N3,
M]3C$;1_Z>+#F*,=WET$BD)[ J!;!'*XSKPIK8#3/*=?$N[@2J,#BEPH.&0[Z
MK39A[S />Y>;\$JJ<!:B$YHMX+^I@%U04Y.]931YC"O!H7ZC(L]EKM)X-6P9
MR-?YLI527W4<;_AQ_%AW=3D=PF#](KP*H05RSE/9%"5SYL!Y)5U4#NP1!L(V
M"5P1 97/$[!H5832]UK"<ZWL?=\:]^B7(Z5<LH>'.%+?A>=+X@2R@H^&_3H^
MV=QL(GXX>W-Q&&:PK]H97CE3T:;(K%+MK95)>% YD0Q-=BLN\7L06NQ("$R@
M9;6+X?LC6.48>$O$C!NGK6LAM4/A6$#)GL$%M$HNO]K?I_QZ=C]O(24H@V.O
M61-]#5H6_,M&3Q*?_Q8AQ:?@XV??BI4,G0U;X=,GB7X__Q)C'M2#:5+EGG[)
MA?3ZF_[8#V.E?VQH'N@F'$YR]M\JIY]ZIX=1BXT70GJ<'8NY*U)#]K1UT3IN
MH$B6Z'B("?8,TEE%#?9^PL8JB1<WPN!!3S&# N3Z@ "Q#38$LY'K!IO\"P8
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M:RTR,#(U,#@S,2YX<V102P$"% ,4    " !<B"A;)W15"7\E  #S/0$ #P
M            @ $W'0  8WET:RUE>#DY7S$N:'1M4$L%!@     #  , NP
' .-"      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>cytk-20250831_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cytk-20250831.xsd" xlink:type="simple"/>
    <context id="C_a19ad6a3-6969-42d7-9e74-94a197fa7296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001061983</identifier>
        </entity>
        <period>
            <startDate>2025-08-31</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_791ea97c-01e6-40e6-9bdb-f2749620ff26">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_8ed50108-0721-4cd7-9e25-34a4987a6afd">0001061983</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_6586939c-dbc3-4ecd-a969-9ede9f3a1d52">8-K/A</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_b33f7397-51cb-45b1-8131-c84db3ca6b07">2025-08-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_a3ba222e-bf7e-4314-99fb-4bf05b419b87">Cytokinetics, Incorporated</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_f9c0e7b5-ddf4-42e5-bdb2-0e5cf6011edb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_a0483d9d-cc5b-4e03-81b7-d374e5a59bb2">000-50633</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_2284ea5f-8763-4994-aaea-81b242166d2d">94-3291317</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_288f1810-f7d2-48da-b85c-32909612a671">350 Oyster Point Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_0c1eaa8c-2fc8-47fc-9fc7-50c0595b565d">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_5348dc27-e025-4721-a6a5-d381fd724ff0">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_377a97a1-3424-4f94-ae59-5fc571da0cd2">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_8cab2d56-f739-463e-a6ae-bcdab602240f">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_0e49bebf-d9bf-4317-8557-dc1cec86df50">624-3000</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_407f0230-0529-4fb7-8cd2-d2b790637509">n/a</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_b45a4ed6-8c8a-4658-9f15-086e110db42a">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_e4adb32e-9579-408e-a7e9-00355882692f">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_2bc4eefb-e3a9-4396-8eb5-cc38ea7b9f98">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_e906ad25-37c2-4904-b4c7-bbe27ac5eb80">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_59a82fe4-4d67-4126-bfb9-be1e14ff1e47">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_e3fc3cff-6cf7-42f0-b010-acee5e478527">CYTK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_3281ab6e-cac9-40d7-a732-beb8a63bad7e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_9457b223-7779-4ea3-8df8-38768e5d6813">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentDescription
      contextRef="C_a19ad6a3-6969-42d7-9e74-94a197fa7296"
      id="F_4c94f51a-7772-473e-8d18-5440addd850f"/>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
